Pediatric brain tumors are the leading cause of childhood cancer mortality. Recurring genetic abnormalities play an essential role in the diagnosis and prognosis of pediatric brain tumors. However, clinical workup has not routinely included whole genome assessment. Here, we present high resolution whole genome array results in 11 pediatric brain tumors. Array identified clinically relevant abnormalities in all samples. Copy number aberrations with targeted therapy implication, GOPC-ROS1 fusion, CDK4 amplification, and NF1 deletion, were detected in 3 cases. In addition, array detected recurring genetic abnormalities, including KIAA1549-BRAF fusion, 19q13.42 amplification, i(17q), and monosomy 6, which assisted accurate histological diagnosis in pediatric brain tumors. In conclusion, our results show that whole genome high-resolution array detects diagnostic and treatment-relevant copy number abnormalities in pediatric brain tumors.
OstromQTGittlemanHFulopJet al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(suppl 4):iv1-iv62.
2.
FontebassoAMJabadoN. Pediatric brain tumors: genomics and epigenomics pave the way. Crit Rev Oncog. 2015;20:271-299.
3.
JonesCKarajannisMAJonesDTWet al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2017;19:153-161.
4.
LouisDNPerryAReifenbergerGet al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-820.
5.
JonesDTKocialkowskiSLiuLet al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673-8677.
6.
KorshunovAMeyerJCapperDet al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118:401-405.
7.
SchwartzentruberJKorshunovALiuXYet al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226-231.
8.
SturmDWittHHovestadtVet al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.
9.
BaxDAMackayALittleSEet al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res. 2010;16:3368-3377.
10.
PaughBSQuCJonesCet al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28:3061-3068.
11.
ZarghooniMBartelsULeeEet al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor α and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28:1337-1344.
JanewayKAPlaceAEKieranMWHarrisMH. Future of clinical genomics in pediatric oncology. J Clin Oncol. 2013;31:1893-1903.
14.
RamkissoonSHBiWLSchumacherSEet al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015;17:1344-1355.
15.
KorshunovARemkeMGessiMet al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010;120:253-260.
16.
KorshunovASturmDRyzhovaMet al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014;128:279-289.
JacobKAlbrechtSSollierCet al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer. 2009;101:722-733.
19.
TabouretELabussiereMAlentornASchmittYMarieYSansonM. LRP1B deletion is associated with poor outcome for glioblastoma patients. J Neurol Sci. 2015;358:440-443.
20.
VizcainoMAShahSEberhartCGRodriguezFJ. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. Hum Pathol. 2015;46:1323-1330.
Debiec-RychterMBiernatWZakrzewskiKKrulWLiberskiPP. Loss of chromosome 22 and proliferative potential in ependymomas. Folia Neuropathol. 2003;41:191-195.
23.
MillerSRogersHALyonPet al. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol. 2011;13:866-879.
RothJJSantiMRorke-AdamsLBet al. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet. 2014;207:111-123.
26.
NikiforovaMNWaldAIMelanMAet al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol. 2016;18:379-387.
27.
GajjarABowersDCKarajannisMALearySWittHGottardoNG. Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol. 2015;33:2986-2998.
28.
DaviesKDDoebeleRC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19:4040-4045.
29.
CharestALaneKMcMahonKet al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer. 2003;37:58-71.
30.
RimkunasVMCrosbyKELiDet al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457.
31.
SueharaYArcilaMWangLet al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res. 2012;18:6599-6608.
32.
SolomonB. Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer. J Clin Oncol. 2015;33:972-974.
33.
ShawATOuSHBangYJet al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-1971.
34.
MazieresJZalcmanGCrinoLet al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.
35.
BuczkowiczPBartelsUBouffetEBecherOHawkinsC. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128:573-581.
36.
Khuong-QuangDABuczkowiczPRakopoulosPet al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124:439-447.
37.
DahlbackHSBrandalPGorunovaLet al. Genomic aberrations in pediatric gliomas and embryonal tumors. Genes Chromosomes Cancer. 2011;50:788-799.
38.
PollackIFBoyettJMYatesAJet al; Children’s Cancer Group. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol. 2003;5:197-207.
39.
RamkissoonSHBandopadhayayPHwangJet al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors [published online January 19, 2017]. Neuro Oncol. doi:10.1093/neuonc/now294.
40.
RamaswamyVRemkeMBouffetEet al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821-831.
41.
PietschTSchmidtRRemkeMet al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014;128:137-149.
42.
EllisonDWDaltonJKocakMet al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381-396.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
